Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

BHVN

Biohaven Ltd.

Pharmaceutical Preparations · SIC 2834CIK 1935979Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
—
Net Income FY2025
$(739.0M)
EPS (Basic, as reported)
$-6.86
Net Margin FY2025
—
ROE FY2025
-1418.8%
Total Equity
$52.0M
Shares Out
151M
Business description

Biohaven Ltd. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itNet income: (119) → (739)
Fiscal yearFY2020FY2021FY2022⚑FY2023FY2024FY2025
Research & development(98)(181)(437)(373)(796)(635)
General & administrative(16)(37)(131)(63)(89)(110)
Total operating expenses(115)(219)(568)(436)(885)(745)
Operating income(115)(219)(568)(436)(885)(745)
Interest & investment income——3182215
Other income (expense), net(4)6(2)27398
Pre-tax income(119)(212)(570)(410)(846)(737)
Income tax expense0(1)0(1)(1)(1)
Net income(119)(214)(570)(408)(846)(739)
EPS — basic($3.01)($5.43)($12.75)($5.73)($9.28)($6.86)
EPS — diluted($3.01)($5.43)($12.75)($5.73)($9.28)($6.86)
Shares outstanding — basic (M)3939457191108
Shares outstanding — diluted (M)3939457191108
  • ⚑ Weighted-average shares changed ×1.58 between FY2022 and FY2023 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.